University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Faculty Publications -- Chemistry Department

Published Research - Department of Chemistry

2016

LIVE, ATTENUATED VACCINES AND METHODS OF MAKING AND
USING
Jiantao Guo
Lincoln, NE, jguo4@unl.edu

Qingsheng Li
University of Nebraska - Lincoln, qli4@unl.edu

Wei Niu
Lincoln, NE, wniu2@unl.edu

Yue Li
Lincoln, NE

Nanxi Wang
Lincoln, NE

Follow this and additional works at: https://digitalcommons.unl.edu/chemfacpub
Part of the Analytical Chemistry Commons, Medicinal-Pharmaceutical Chemistry Commons, and the
Other Chemistry Commons

Guo, Jiantao; Li, Qingsheng; Niu, Wei; Li, Yue; and Wang, Nanxi, "LIVE, ATTENUATED VACCINES AND
METHODS OF MAKING AND USING" (2016). Faculty Publications -- Chemistry Department. 227.
https://digitalcommons.unl.edu/chemfacpub/227

This Article is brought to you for free and open access by the Published Research - Department of Chemistry at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Faculty Publications -Chemistry Department by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

US 20160375.128A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2016/0375128A1
Guo et al.

(43) Pub. Date:

(54) LIVE, ATTENUATED VACCINES AND
METHODS OF MAKING AND USING

Related U.S. Application Data
(60) Provisional application No. 61/937,712, filed on Feb.

(71) Applicant: NUtech Ventures, Lincoln, NE (US)

10, 2014.
Publication Classificati

(72) Inventors: Jiantao Guo, Lincoln, NE (US);

Qingsheng Li, Lincoln, NE (US); Wei

O

SSCO

(51) Int. Cl.

Niu, Lincoln, NE (US); Yue Li,
Lincoln, NE (US); Nanxi Wang,

Lincoln, NE (US)

Dec. 29,9 2016

A6IR 39/2I
CI2N 7/00

(2006.01)
(2006.01)

(52) U.S. Cl.

CPC ................. A61K 39/21 (2013.01): CI2N 7/00

(21) Appl. No.:

15/117,949

(22) PCT Filed:

Feb. 10, 2015

(86). PCT No.:

PCT/US 15/15229

(57)

Aug. 10, 2016

A live, attenuated HIV vaccine is provided, and methods of
making a attenuated HIV Vaccine are provided.

S 371 (c)(1),
(2) Date:

(2013.01); C12N 2740/16034 (2013.01); C12N
2740/16021 (2013.01); C12N 2740/16051
(2013.01); A61 K 2039/5254 (2013.01)
ABSTRACT

Patent Application Publication

Dec. 29, 2016 Sheet 1 of 12

US 2016/0375.128A1

O O O
H

HN COOH
paAZPhe

H
NCOH HNCOOH
H2 N1a COOH

plPhe

O

HNors

plNitroPhe

O

plAcPhe

Ol

HNo-

.. .. HN COOH
AZLys

MeoLys

FIG. 1A

NbZLys

NO2

ors

Patent Application Publication

Dec. 29, 2016 Sheet 2 of 12

US 2016/0375.128A1

Patent Application Publication

Dec. 29, 2016 Sheet 3 of 12

US 2016/0375.128A1

a ?ororo
HN CO
AZF

H3N CO2
ACF

EGFP
293T Cell

FIG. 2

H3N CO2
Odo F

Patent Application Publication

Dec. 29, 2016 Sheet 4 of 12

FIG. 3

US 2016/0375.128A1

Patent Application Publication

NL-GL-Wt

Dec. 29, 2016 Sheet 5 of 12

US 2016/0375.128A1

NL-GL-Tyra OTAG
S

S

Patent Application Publication

Dec. 29, 2016 Sheet 6 of 12

US 2016/0375.128A1

w

5.10 x 10

pSUMA-Tyr59
131 x 10

FIG. 5

pSUMA-Trp36Gln127
5.12 x 10

Patent Application Publication

Dec. 29, 2016 Sheet 7 of 12

US 2016/0375.128A1

Patent Application Publication

Dec. 29, 2016 Sheet 8 of 12

US 2016/0375.128A1

S

8

Š

E.

S8

FIG. 7

Patent Application Publication

$

SSS.

Dec. 29, 2016 Sheet 9 of 12

US 2016/0375.128A1

Patent Application Publication

7
8
|
Z
||
0

009

Dec. 29, 2016 Sheet 10 of 12

US 2016/0375.128A1

Patent Application Publication

Dec. 29, 2016 Sheet 11 of 12

US 2016/0375.128A1

Patent Application Publication

Dec. 29, 2016 Sheet 12 of 12

US 2016/0375128A1

US 2016/0375128A1

Dec. 29, 2016

LIVE, ATTENUATED VACCINES AND

0014. In some embodiments, the article of manufacture

METHODS OF MAKING AND USING

further can include a host cell.

CROSS REFERENCE TO RELATED
APPLICATIONS

0001. This application claims the benefit of priority under
35 U.S.C. S 119(e) to U.S. Application No. 61/937,712, filed
on Feb. 10, 2014.
TECHNICAL FIELD

0002 This disclosure generally relates to vaccines.
BACKGROUND

0003. Historically, vaccines have been the best weapon
against the world's deadliest infectious diseases, including
Smallpox, polio, and yellow fever. Live, attenuated vaccines
in general tend to elicit the most potent protective immunity,
since it is the closest mimic of a natural infection. Therefore,

live, attenuated vaccines elicit strong protective cellular and
antibody responses and often confer a lifelong immunity
with only one or two dosings.
0004. This disclosure provides a novel method for pro
ducing live-attenuated therapeutic vaccines against a wide
array of pathogenic viruses or bacteria.

0015. In some embodiments, the host cell includes and
expresses at least one transgene encoding a first Suppressor
tRNA and a first corresponding aminoacyl-tRNA synthetase
pair that recognizes the unnatural amino acid.
0016. In some embodiments, an article of manufacture
further can include a photoreactive amino acid. In some
embodiments, the UAA* is a photoreactive amino acid.
0017. In some embodiments, the host cell further
includes at least one transgene encoding a second suppressor
tRNA and a second corresponding aminoacyl-tRNA syn
thetase pair that recognizes the photoreactive amino acid.
0018. Unless otherwise defined, all technical and scien
tific terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
methods and compositions of matter belong. Although meth
ods and materials similar or equivalent to those described
herein can be used in the practice or testing of the methods
and compositions of matter, Suitable methods and materials
are described below. In addition, the materials, methods, and

examples are illustrative only and not intended to be limit
ing. All publications, patent applications, patents, and other
references mentioned herein are incorporated by reference in
their entirety.

SUMMARY

DESCRIPTION OF DRAWINGS

0005 Alive, attenuated vaccine is provided, and methods
of making a live, attenuated vaccine are provided.
0006. In one aspect, a live, attenuated HIV vaccine is
provided, where the genome of the HIV includes at least one
first mutation in an essential region. Typically, the first

0019 FIG. 1 is a schematic showing the use of blank
codons to control HIV replication. Panel A is the structure of
representative unnatural amino acids (UAA); and Panel B
is a schematic showing how the replication of HIV is
controlled using blank codons and UAA*s.
0020 FIG. 2 is data showing controlled EGFP expression
in 293T cells. Panel (A) is the chemical structures of
4-azidophenylalanine (AZF), 4-acetylphenylalanine (AcF).
and 4-iodophenylalanine (IodoF); Panel (B) is a schematic
showing EGFP with an Amber codon at position 40; Panel
(C) demonstrates EGFP expression in the presence of the

mutation is a nonsense mutation.

0007. In some embodiments, the genome of the HIV
further comprises at least one transgene in a non-essential
region, the transgene encoding a Suppressor tRNA and a
corresponding aminoacyl-tRNA synthetase.
0008. In some embodiments, the genome of the HIV
further comprises at least one second mutation in an essen
tial region. Typically, the second mutation results in a codon
encoding for an unnatural amino acid. In some embodi
ments, the unnatural amino acid is a photoreactive amino
acid such as, for example, a photocaged amino acid (e.g.,
ONBK and ONBL).
0009. In some embodiments, the essential region is the
gag gene or the protease gene. In some embodiments, the
non-essential region is between the env gene and the nef
gene.

0010. In another aspect, a method of making a live,
attenuated HIV vaccine is provided. Such a method gener
ally includes infecting a host cell with a live, attenuated HIV
vaccine as described herein; and purifying the live, attenu
ated HIV vaccine.

0011. In some embodiments, the method further can
include exposing the infected host cell to light. In some
embodiments, the light is UV light (e.g., 365 nm light).
0012. In some embodiments, the host cell includes at
least one transgene encoding the Suppressor tRNA and the
corresponding aminoacyl-tRNA synthetase.
0013. In yet another aspect, an article of manufacture for
producing a live, attenuated HIV vaccine is provided. Gen
erally, such an article of manufacture includes a live, attenu
ated HIV vaccine as described herein; and at least one

unnatural amino acid (UAA).

tRNA-AZFRS pair and 1 mM of AZF; Panel (D) demon
strates EGFP expression in the presence of the tRNA'-

AZFRS pair, but without AZF. Scale bars, 200 Lum.
0021 FIG. 3 is data demonstrating that HIV-1 replication
can be controlled with Amber suppression. Panel (A) shows
a p24 assay after transfection of 293T with pSUMA variants.
The absorbance values were determined at 450 nm after the

colorimetric reactions were stopped by the addition of 1 M
H2504. Well #11 was used as a blank for all measurements.

Well #1, wild-type pSUMA only; Well #2, wild-type

pSUMA+tRNA'-AZFRS pair+1 mM AZF; Well #3,
pSUMA-Tyr132+tRNA'-AZFRS pair, without AZF; Well
#4, pSUMA-Tyr132+tRNA-AZFRS pair, with 1 mMAZF;
Well #5, pSUMA-Tyr132+tRNA'-TyrRS pair; Well #6,
pSUMA-Tyr132; Well #7, pSUMA-Ala119.--tRNA
AZFRS pair, without AZF; Well #8, pSUMA-Ala119.--

tRNA'-AZFRS pair, with 1 mM AZF; Well #9, pSUMA
Leu365+tRNA-AZFRS pair, without AZF; Well #10,
pSUMA-Leu365+tRNA-AZFRS pair, with 1 mM AZF;

Well #11, negative ELISA control, no p24; Well #12, posi
tive ELISA control, 125 pg/ml p24; Panels (B)-(I) are data
from infection assays with TZM-bl cells. Panel (B) shows
cells infected with virus collected from the sample described
in Well #1; Panel (C) shows cells infected with virus
collected from the sample described in Well #2; Panel (D)
shows cells infected with virus collected from the sample

US 2016/0375128A1

described in Well #4: Panel (E) shows cells infected with
virus collected from the sample described in Well #3; Panel
(F) shows cells infected with virus collected from the sample
described in Well #5; Panel (G) shows cells infected with
virus collected from the sample described in Well #6; Panel
(H) shows cells infected with virus collected from the
sample described in Well #8; Panel (I) shows cells infected
with virus collected from the sample described in Well #10.
Scale bars, 100 um.
0022 FIG. 4 is data showing expression and infection
with pNL-GI variants. Panel (A) is a fluorescence image of
pNL-GI; Panel (B) is a fluorescence image of pNL-GI

Tyra.0+tRNA'-AZFRS pair, with 1 mM AZF; Panel (C)
shows infection of TZM-bl cells with virus collected from

the cells shown in FIG. 4, Panel (A); Panel (D) shows
infection of TZM-bl cells with virus collected from the cells

shown in FIG. 4, Panel (B). Scale bars, 200 um.
0023 FIG. 5 is data showing infection assays with TZM
bl cells. Panel (A) shows cells infected with wild-type
pSUMA; Panel (B) shows cells infected with pSUMA
TyrS9; Panel (C) shows cells infected with pSUMA
Trp36Gln127. Scale bars, 200 um. The doses used for
infection are shown as Tissue Culture Infectious Dose 50

(TCID50). The wild-type pSUMA was diluted 4-fold and the
pSUMA mutants were concentrated 15-fold in order to
adjust the infectious dose of each variant to a similar level.
0024 FIG. 6 is data showing p24 assays after transfection
of 293T with pSUMA variants. Well #1, wild-type pSUMA
control; Well #2, negative ELISA control, no p24; Well #3,
positive ELISA control, 125 pg/ml p24; Well #4, pSUMA

Tyr132+tRNA'-AcFRS pair, with 1 mM AcF: Well #5,
pSUMA-Alal 19+tRNA'-AclfRS pair, with 1 mM AcF:
Well #6, pSUMA-Leu365+tRNA"-AcERS pair, with 1
mM AcF: Well #7, pSUMA-Tyr132+tRNA'-IodoFRS pair,
with 1 mM IodoF: Well #8, pSUMA-Ala119.--tRNA
IodoFRS pair, with 1 mM IodoF: Well #9, pSUMA
Leu365+tRNA'-IodoFRS pair, with 1 mM IodoF. Well #2

was used as a blank for p24 assays.
0025 FIG. 7 shows infection assays with TZM-bl cells

using thNA'-AcFRS pair and tRNA'-IodoFRS pair.
Panel (A) shows cells infected with virus collected from
pSUMA-Tyr132+tRNA'-AcERS pair+1 mM AcF; Panel
(B) shows cells infected with virus collected from pSUMA

Alal 19+tRNA'-AcERS pair+1 mM AcF: Panel (C) shows
cells infected with virus collected from pSUMA-Leu365+
tRNA'."-AcPRS pair+1 mM AcF; Panel (D) shows cells
infected with virus collected from pSUMA-Tyr132+
tRNA'."-IodoFRS pair+1 mM IodoF; Panel (E) shows cells
infected with virus collected from pSUMA-Ala 1 19
tRNA'."-IodoFRS pair+1 mM IodoF: (F) infected with virus
collected from pSUMA-Leu365+tRNA'."-IodoFRS pair+1
mM IodoF. Scale bars, 200 um.
0026 FIG. 8 shows infection assays with TZM-bl cells

using trNA'"-AZFRS pair. Panel (A) shows cells infected
with virus collected from pSUMA-Ala119--tRNA-AZFRS
pair, without 1 mMAZF; Panel (B) shows cells infected with
virus collected from pSUMA-Leu365+tRNA-AZFRS
pair, without 1 mMAZF; Panel (C) shows cells infected with
pSUMA-TyrS9+tRNA-AZFRS pair, without 1 mM AZF
(the harvested viruses were concentrated 15 folds); Panel
(D) shows cells infected with pSUMA-Trp36Gln127+

tRNA'."-AZFRS pair, without 1 mM AZF (the harvested
viruses were concentrated 15 folds). Scale bars, 200 um.
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(0027 FIG. 9 shows mass spectrometry analysis of EGFP
containing AZF at position 40. They ions are marked in the
spectrum. The amino acid sequence of the peptide fragment,
FSVSGEGEGDATAZFGK (SEQ ID NO:23), from mutant
EGFP containing AZF is shown on top. The amber mutation
site contained exclusively 4-aminophenylalanine (aminoF),
which is the reduction product of AZF. This observation is
consistent with previous reports on the mass spectrometry
analyses of AZF-containing proteins.
0028 FIG. 10 is a schematic showing photo-regulation of
protein function. Panel (A) shows the structures of ONBY
and ONBK; Panel (B) shows the restoration of protein
function with UV light.
0029 FIG. 11 is data demonstrating the incorporation of
ONBY and ONBK into EGFP-Y40 in 293T cells. Panel (A)
shows 293T cells containing pEGFP-Y39TAG and pcDNA
U6-PylT-ONBY in the presence of 0.4 mM ONBY: Panel
(B) shows 293T cells containing pEGFP-Y39TAG and
pcDNA-U6-PylTONBY in the absence of 0.4 mMONBY:
Panel (C) shows 293T cells containing pEGFP-Y39TAG
and pCMV-ONBK in the presence of 1 mM ONBK; Panel
(D) shows 293T cells containing pEGFP-Y39TAG and
pCMV-ONBK in the absence of 1 mM ONBK.
0030 FIG. 12 is data demonstrating the infectivity of
pSUMA-d1 d2-AZFRS and pSUMA-d1 d2-TyrRS. Panel (A)
shows the infection of TZM-bl cells with pSUMA-d1 d2
AZFRS: Panel (B) shows the infection of TZM-bl cells with
pSUMA-d1 d2-TyrRS.
0031 FIG. 13 is data demonstrating EGFP expression
and infectivity of pSUMA-EGFP mutant. Panel (A) shows a
fluorescence image of 293T cells containing pSUMA
EGFP, Panel (B) shows the infection of TZM-bl cells with
pSUMA-EGFP-derived HIV-1 mutant.
DETAILED DESCRIPTION

0032 Genetic code expansion with evolved orthogonal
suppressor tRNA-aminoacyl-tRNA synthetase (aaRS) pair
has been widely applied to the site-specific incorporation of
unnatural amino acids (UAA's) having unique chemical and
physical properties into proteins in living cells to facilitate
the study of protein structure and function. This disclosure
provides a new application for genetic code expansion that
couples a UAA*-mediated blank codon (i.e., a codon that
does not encode a natural proteinogenic amino acid) Sup
pression of the virus assembly process in the development of
a live, attenuated vaccine. Using this strategy, replication of
the infectious agent can be precisely controlled by UAA*s,
thereby creating a live, attenuated vaccine.
0033. This disclosure describes the use of an unnatural
amino acid (UAA)-mediated blank codon Suppression sys
tem (FIG. 1). It is demonstrated herein that introducing
blank codons within essential regions of the HIV genome
can prevent the proper translation and assembly of viable
virus particles. However, live and functional HIV particles
can be assembled in the presence of a special tRNA
aminoacyl-tRNA synthetase pair that is able to decode the
blank codon. The assembled virus particles can be used as a
live, attenuated vaccine. Since the host does not contain the

special tRNA-aminoacyl-tRNA synthetase pair, the virus
can undergo only one cycle of infection and is not able to
replicate, which attenuates the virus. To make the system as
stringent as possible, specific tRNA-aminoacyl-tRNA syn
thetase pairs that only recognize unique UAAs are used. In
other words, the unique UAA*s are not present in the host
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and, preferably, are not present in nature. The UAA*mediated blank codon Suppression system described herein
provides the ability to turn on and off replication cycles of
the virus in vivo using UAA* as the control element.
0034) While the fidelity of UAA* incorporation is gen
erally comparable to the fidelity of amino acid incorporation
in nature, the possibility remains that the virus could regain
functional replication by mutating a nonsense codon back to
a sense codon given the high genetic variability exhibited by
HIV and viruses in general. Thus, the introduction of more
than one nonsense codon (e.g., two nonsense codons, three
nonsense codons, four nonsense codons) into one or more
essential regions (e.g., two different essential regions) of the
virus can increase the control over virus replication. Simply
by way of example, if the virus mutation rate is assumed to

be approximately 3x10 per nucleotide per cycle of repli

cation (Rambaut et al., 2004, Nat. Rev. Genet., 5:52-61) and
the virus life cycle is assumed to be one day, the possibility
of mutating one or two nonsense codons back to sense
codons is approximately 1% and 0.01%, respectively, within
the human life span (for purposes herein, assumed to be 100
years). In addition, nonsense mutations can be introduced
into essential regions that exhibit a lower mutation rate, even
further reducing the likelihood that a mutant would regain
virulence.

0035. While HIV was used herein to exemplify the meth
ods, a similar approach also can be used to generate or
improve the safety of live, attenuated vaccines for any
number of infectious viruses or bacteria.

Live, Attenuated Vaccines and Methods of Making
0036. The sequence of the human immunodeficiency
virus (HIV) genome is known and can be found at GenBank
Accession No. AF033819.3. HIV includes two copies of
non-covalently linked, un-spliced, positive-sense single
stranded RNA enclosed by a conical capsid. The RNA
component is less than 10 kb (i.e., 9749 nucleotides in
length) and the nucleocapsid associates with the genomic
RNA (one molecule per hexamer) to protect the RNA from
attach by nucleases.
0037. The HIV genome encodes a number of essential
structural proteins including the group-specific antigen (gag)
protein, the polymerase (pol) protein, and the envelope (env)
protein. The gag gene encodes the precursor Gag polypro
tein that is processed by the viral protease during maturation.
The pol gene encodes the reverse transcriptase and RNase H
enzymes, which are required to produce DNA from the RNA
template, as well as an integrase and a protease. The
integrase is required to integrate the double-stranded viral
DNA into the host genome, and the protease is required to
cleave the precursor Gag polyprotein to produce Some of the
structural proteins. The env gene encodes gp160, which is
cleaved by a host protease and results in a surface glyco
protein that ultimately embeds in the viral envelope and
enables the virus to attach to and fuse with target cells.
0038. The HIV genome also contains several essential
regulatory elements including the HIV trans-activator (tat)
and the regulator of expression of virion proteins (rev). The
tat protein plays an important role early in HIV infection in
regulating the reverse transcription of viral genome RNA,
ensuring efficient synthesis of viral mRNAS and regulating
the release of virions from infected cells. Given its role in

infection and transcription, the tat protein is essential for the
survival of HIV. The rev protein binds to the viral genome
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via an arginine-rich RNA-binding motif that also acts as a
nuclear localization signals (NLS), which results in the
transport of the rev protein into the nucleus during viral
replication. The rev protein is important for the synthesis of
major viral proteins and is hence essential for viral replica
tion.

0039. In addition, the HIV genome contains a number of
accessory regulatory proteins that generally are considered
non-essential to the virus. Accessory regulatory proteins
include the lentivirus protein R (vpr), the negative factor
(nef) protein, the viral infectivity factor (vif), and the virus
protein U (vpu). The Vpr protein is a virion-associated,
nucleocytoplasmic shuttling regulatory protein. It is
believed to play an important role in replication of the virus,
specifically, nuclear import of the pre-integration complex.
The Vpr protein also appears to cause its host cells to arrest
their cell cycle in the G2 phase, which activates the host
DNA repair machinery to enable integration of the viral
DNA. In addition, the nef protein is a N-terminal myristoy
lated membrane-associated phosphoprotein involved in mul
tiple functions during the replication cycle of the virus
including, for example, apoptosis and increasing virus infec
tivity. The Vif protein is a highly conserved, 23 kDa phos
phoprotein important for the infectivity of HIV-1 virions
depending on the cell type, and the Vpu protein is a class I
oligomeric integral membrane phosphoprotein with numer
ous biological functions.
0040. As indicated herein, an unnatural amino acid
(UAA)-mediated blank codon Suppression system (FIG. 1)
has been developed and used to prevent the proper transla
tion and assembly of viable virus particles by introducing at
least one (e.g., one or more; e.g., at least two, at least three)
UAA*-mediated blank codons into one or more essential

regions of the HIV virus. It would be appreciated by a skilled
artisan that UAA*-mediated blank codons also can be

referred to as “nonsense mutations.” As used herein, a

“nonsense mutation” refers to a mutation that produces a
codon (e.g., an amber codon, an ochre codon, an opal or
umber codon) that does not encode a natural proteinogenic
amino acid. As described herein, however, the system allows
for assembly of live and functional HIV particles in the
presence of a corresponding tRNA, referred to herein as a
“suppressor tRNA. For the suppressor tRNA to be present
and capable of decoding the blank codon, the system further
requires the corresponding aminoacyl-tRNA synthetase
(aaRS). It would be understood that the corresponding
suppressor tRNA and aminoacyl-tRNA synthetase often
times are referred to as a “pair.”

0041. Two systems, E coli tRNA'-tyrosyl-tRNA syn
thetase (TyrRS) pair and archaeal tRNA-pyrrolysyl-tRNA

synthetase (PylRS) pair, have been developed to decode
either nonsense (Liu et al., 2007, Nat. Methods, 4:239-44:
Chen et al., 2009, Angew. Chem. Int. Ed., 48:4052-5; Wang
et al. 2007, Nat. Neurosci., 10:1063-72) or frameshift (Niu
et al., 2013, ACS Chem. Biol. 8:1640-5) codons in mam
malian cells. However, the complicated assembly process of
human viruses has made it very challenging to genetically
incorporate mutations, and particularly nonsense mutations,
into the proteins of live human viruses using either of the
above two systems. This disclosure, however, has accom
plished that feat.

I0042 Specifically, as described herein, a tRNA'-4-azi
dophenylalanyl-tRNA synthetase (AZFRS) pair, a tRNA'-

4-acetylphenylalanyl-tRNA synthetase (AcFRS) pair, and a
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tRNA"-4-iodophenylalanyl-tRNA synthetase (IodoFRS)
pair (see, for example, Liu et al., 2007, Nat. Methods,
4:239-44) were used. All three amino acids have similar
sizes to that of tyrosine, and the AZF and AcF molecules
(FIG. 2A) also contain unique functional groups that allow
selective modification of viral proteins through bioorthogo
nal reactions. The methods and systems described herein,

however, are not limited to either an Ecoli tRNA"-tyrosyl
tRNA synthetase (TyrRS) pair or an archaeal tRNA

pyrrolysyl-tRNA synthetase (PylRS) pair; the methods and
systems described herein are amenable to virtually any
suppressor tRNA-aminoacyl-tRNA synthetase pair that are
identified or designed.
0043. The HIV genome can be engineered to contain
multiple and different mutations within one or more essen
tial regions, which further attenuates and controls the virus.
For example, a second mutation can be a mutation that
encodes for a second unnatural amino acid (UAA) within
the same or a different essential region. In some embodi
ments, a second or further mutation can encode, for

example, a photoreactive amino acid. Photoreactive amino
acids are known in the art and include, for example, pho
tocaged amino acids (e.g., ONBK, ONBL) that, upon expo
Sure to light of a particular wavelength, revert to the natural
amino acid.

0044. A mutation as described herein can be the result of
a point mutation, an insertion, a deletion, a substitution, or
combinations thereof. Introducing a mutation into a
sequence is known in the art, and one or more mutations can
be introduced into a viral genome using routine methods
Such as, without limitation, PCR-mediated mutagenesis or
other recombinant nucleic acid techniques (e.g., restriction
enzyme digestion, chemical synthesis, ligation, and combi
nations thereof).
0045. To suppress a mutation as described herein (e.g., a
nonsense mutation), the suppressor tRNA-aminoacyl-tRNA
synthetase pair can be provided on at least one transgene,
operably linked to one or more expression elements. Expres
sion elements include nucleic acid sequences that direct and
regulate expression of coding sequences. One example of an
expression element is a promoter sequence. Expression
elements also can include introns, enhancer sequences,
response elements, or inducible elements that modulate
expression of a nucleic acid. Expression elements can be of
viral origin or bacterial, yeast, insect, or mammalian origin,
and transgenes or vectors containing one or more transgenes
can contain a combination of expression elements from
different origins.
0046. It would be appreciated by a skilled artisan that the
one or more transgenes encoding a Suppressor tRNA and the
corresponding aminoacyl-tRNA synthetase can be contained
within one or more vectors. Vectors, including expression
vectors, are commercially available or can be produced by
recombinant DNA techniques routine in the art. A vector
containing a nucleic acid can have expression elements
operably linked to such a nucleic acid, and further can
include sequences such as those encoding a selectable
marker (e.g., an antibiotic resistance gene). As used herein,
operably linked means that a promoter or other expression
element(s) are positioned relative to a coding sequence so as
to direct or regulate expression of the nucleic acid (e.g.,
in-frame).
0047 One or more vectors containing at least one trans
gene (i.e., encoding a Suppressor tRNA and corresponding
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aminoacyl-tRNA synthetase pair) can be introduced into a
host cell. As used herein, “host cell refers to the particular
cell into which the nucleic acid is introduced and also

includes the progeny of Such a cell that carry the vector. A
host cell can be a prokaryotic or eukaryotic cell. For
example, a transgene as described herein can be expressed
in bacterial cells such as E. coli, or in yeast, plant cells, or
mammalian cells (e.g., human 293T cells). Other suitable
host cells are known to those skilled in the art. Many
methods for introducing nucleic acids into host cells, both in
vivo and in vitro, are well known to those skilled in the art

and include, without limitation, electroporation, calcium
phosphate precipitation, polyethylene glycol (PEG) trans
formation, heat shock, lipofection, microinjection, and viral
mediated nucleic acid transfer. In some cases, the choice of

methods will depend upon whether integration into the
genome of the host cells is desired or required, or whether
transient expression or extrachromosomal expression from a
vector (e.g., a replicating plasmid) is desired.
0048 Alternatively, and as discussed herein, the at least
one transgene (e.g., at least two transgenes, at least three
transgenes) encoding the Suppressor tRNA and correspond
ing aminoacyl-tRNA synthetase pair can be introduced into
the HIV genome. In this embodiment, the at least one
transgene is introduced into a non-essential region of the
HIV genome that allows transcription and translation and
does not interfere with replication and packaging. It would
be appreciated that, from a safety perspective, expression of
the suppressor tRNA and corresponding aminoacyl-tRNA
synthetase pair from the HIV genome requires that the
nonsense mutation encodes for an amino acid that does not

exist in the host and, preferably, does not exist in nature.
0049 Methods of maintaining a live, attenuated HIV
vaccine are known in the art, and typically include infecting
a host cell with the live, attenuated HIV vaccine. The host

cell, under these circumstances, typically is determined by
the virus host specificity. As discussed herein, if the viral
genome does not contain a transgene encoding the Suppres
sor tRNA and corresponding aminoacyl-tRNA synthetase
pair, then the at least one transgene encoding the Suppressor
tRNA and corresponding aminoacyl-tRNA synthetase pair
needs to be provided by the host cell in order to suppress the
mutation. In addition, if any of the mutations include a
photoreactive amino acid, then the appropriate light needs to
be provided in order to suppress the mutation. Following
infection, the live, attenuated HIV vaccine described herein

can be purified. As used herein, purifying a live, attenuated
HIV vaccine refers to a process that removes the vaccine
from the host cell or from the culture in which the host cell

is growing.
0050. In addition, an article of manufacture if provided
for producing or maintaining a live, attenuated HIV vaccine.
An article of manufacture as described herein can include a

live, attenuated HIV vaccine as described herein, and at least

one unnatural amino acid (UAA). An article of manufac
ture also can include an appropriate host cell, which, if
necessary, includes the at least one transgene encoding the
suppressor tRNA and the corresponding aminoacyl-tRNA
synthetase pair that recognizes the unnatural amino acid. In
Some embodiments, an article of manufacture can include

one or more (e.g., two or more, three or more) photoreactive
amino acids and, if necessary, at least one transgene encod
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ods 4:239-44) and inserted into pcDNA3.1-tRNA" behind

ing the Suppressor tRNA and the corresponding aminoacyl
tRNA synthetase pair that recognizes the photoreactive

the non-regulated CMV promoter to afford plasmid pac

amino acid.

FRS.

0051. In accordance with the present invention, there
may be employed conventional molecular biology, micro
biology, biochemical, and recombinant DNA techniques
within the skill of the art. Such techniques are explained
fully in the literature. The invention will be further described
in the following examples, which do not limit the scope of
the methods and compositions of matter described in the

0063 plodoFRS:
0064. The IodoFRS-encoding gene was PCR amplified
from plasmid pSWAN-plpaRS (Liu et al., 2007, Nat. Meth

claims.
EXAMPLES

Example 1
General

0052 All chemicals and DNA oligomers were obtained
from commercial sources and used without further purifi

ods 4:239-44) and inserted into pcDNA3.1-tRNA" behind

the non-regulated CMV promoter to afford plasmid plod
OFRS.

0065 pEGFP-TAG40:
0066. The EGFP-encoding gene containing an amber
stop codon (UAG) at a permissive site (Tyr20) was inserted

into pcDNA3.1-tRNA' behind the non-regulated CMV

promoter to afford plasmid plGFP-TAG40.
0067 pSUMA Mutants:
0068. Overlapping PCR was used to introduce amber
mutations onto the HIV-1 genome that is encoded by plas
mid pSUMA. The following primers were used to introduce
amber mutations:

cation.

0053. Unnatural amino acids (UAA*s), 4-azidophenyl
alanine (AZF) and 4-iodophenylalanine (IodoF), were pur
chased from Bachem. The synthesis of 4-acetylphenylala
nine (AcF) follows the procedure that was previously
reported (Wang et al., 2003, PNAS USA, 100:56-61).
0054 HIV-1 clone, pSUMA.c/2821, Catil 11748, referred
to herein as “pSUMA”, is an infectious molecular clone of
a founder/transmitter HIV-1 virus and was obtained through
the NIH AIDS Reagent Program, Division of AIDS, NIAID,
NIH, from Dr. John Kappes and Dr. Christina Ochsenbauer.
0055 E. coli DH10B and GeneHogs were used for rou
tine cloning and DNA propagation. E. coli Stb1-2 (Life
Technologies) was use for pSUMA manipulations.
0056 Standard molecular biology techniques (Sambrook
et al., 2000, Molecular Cloning: A Laboratory Manual. Third
Ed., Cold Spring Harbor Laboratory Press) were used
throughout.

pSUMA-Tyr132
(SEQ ID NO: 1)
5 - CTAGAACGATTCGCAGTTAACCCTG-3

(SEQ ID NO: 2)
s' - GTTCTGCACTATAGGCTAATTTTGGCTGACCTGGCTG-3'

(SEQ ID NO : 3)
5-TAGCCTATAGTGCAGAACCTCCAG-3

(SEQ ID NO : 4)
s' - GTGCCTATAGCTTTGTGTCCACAG-3'

pSUMA-Alal19
(SEO ID NO; 5)
5 - CTAGAACGATTCGCAGTTAACCCTG-3

(SEQ ID NO : 6)
5'-TTTCCTGCGTCAGCCtaTGCTTGCTGTGCTTTTTTCTTAC-3'

(SEO ID NO: 7)
5 - CTGACGCAGGAAACAACAGCCAG-3'

Example 2

(SEQ ID NO: 8)
s' - GTGCCTATAGCTTTGTGTCCACAG-3'

Plasmid Construction

0057 pcDNA3.1-tRNA'":
0058. The suppressor tRNA" was derived from E. coli.
The G35 of the tRNA" was mutated to C to generate CUA
anticodon. The tRNA' gene lacking 3'-CCA but with a

3'-TTTTTCT sequence was PCR amplified. A human U6
promoter was PCR amplified from pCMV-pylRSNBK-1
(Chen et al., 2009, Angew. Chem. Int. Ed., 48:4052-5 and

121:4112-5) and added in front of the tRNA gene by
overlapping PCR. The U6-tRNA' gene cassette was PCR

pSUMA-Leu365
(SEO ID NO: 9)
5 - CAAAGTAAGACAATATGATCAGGTAAC-3'

(SEQ ID NO: 10)
s" - CACCTCTACAGATGTTCTCTCAGTTCCTC-3'

(SEQ ID NO: 11)
5 - CATCTGTAGAGGTGGGGATTTACCACAC-3'

(SEQ ID NO: 12)
5'-GCTTCCCATGTTTCTCTTTGTATG-3

amplified and inserted into pcDNA3.1/hygro(+) (Life Tech
nologies) in front of the CMV promoter to afford pcDNA3.

pSUMA-Tyr59

1-tRNA'.

5 - CTAGAACGATTCGCAGTTAACCCTG-3

0059 pAZFRS:
0060. The AZFRS-encoding gene was PCR amplified
from plasmid pSWAN-pAZpaRS (Liu et al., 2007, Nat.

5'-ATTTCTATGGTTACCTGATCCTATTGTCTTACTTTGATAAAAC-3'

Methods 4:239-44) and inserted into pcDNA3.1-tRNA'."

behind the non-regulated CMV promoter to afford plasmid
pAZFRS.
0061 pAcFRS:
0062. The AcFRS-encoding gene was PCR amplified
from plasmid pSWAN-pApaRS (Liu et al., 2007, Nat. Meth

(SEQ ID NO: 13)
(SEQ ID NO: 14)

pSUMA-Trp36Gln127
(SEQ ID NO: 15)
5 - GTAGAGGATCCACTAGTAAC-3'

(SEQ ID NO: 16)
5'-TAGCTCCCTGCTTGCCTATACTATATGTTTTAATTG-3'
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(SEO ID NO: 17)

0.45-micron filter. The virus was used directly or aliquoted
into sterile screw-cap vials and stored at -80° C.

(SEQ ID NO: 18)

Example 5

0069 pNL-GI-Tyr-10:
0070. Overlapping PCR was used to introduce amber
mutations onto the GFP gene that is encoded on plasmid
pNL-GI (Collins et al., 1998, Nature, 391:397-401). The
following primers are used to introduce the amber mutation:

p24 Assay

- Continued
5 " - GGCAAGCAGGGAGCTAGAAC-3

s' - GTGCCTATAGCTTTGTGTCCACAG-3'

(SEQ ID NO: 19)
5 - GCTATAAGACGCGTCCACCATG-3

(SEQ ID NO: 2O)
s' - CCTAGGTGGCATCGCCCTC-3'

(0073 P24 assay was measured with Retrotek HIV-1 p24
Antigen ELISA 2.0 by following standard procedures pro
vided by the manufacture (ZeptoMetrix Corporation).
Briefly, 200 ul cell culture samples, the standard, and the
control were added to the monoclonal antibody-coated
micro-plate wells and incubated at 37°C. for 1.5 hour. After
washing and the addition of antibody-HRP conjugate, the
micro-plate was incubated at 37° C. for one hour. Plates
were then washed and the HRP-substrate was added for

color development. The reactions were stopped by the
(SEQ ID NO: 21)

5 - CGATGCCACCTAGGGAAAGCTGACCCTGAAGTTC-3'

(SEQ ID NO: 22)
s' - CGTCTAGATTACTTGTACAGCTCATC-3'

addition of 1 M H2504 and absorbance values were deter

mined at 450 nm. The amount of p24 is determined by
interpolation from a point-to-point plot or from a linear
regression analysis of the standard curve.
Example 6

Example 3
Protein Expression and Purification
0071) 293T cells were grown in media containing
DMEM, 10% FBS (v/v), and 2 mM L-glutamine at 37° C.
in a humidified atmosphere of 5% CO (v/v). When cells
reached 60-70% confluency, they were transfected with
plasmids pEGFP-40TAG and pAZFRS using Lipo
fectamineTM 2000 (Life Technologies) according to the
manufacturer's protocol (36 uL Lipofectamine 2000+12 lug
of p AZFRS+12 ug of pEGFP-TAG40 for 12 mL cell culture

in 75 cm cell-culture flask). Six hours posttransfection, the

culture medium was carefully removed and replaced with 12
ml of fresh medium containing 1 mMAZF. Cells were grown
for an additional 36 h before being washed with DPBS,
lysed with RIPA buffer (Thermo Scientific), and partially
purified using Ni-NTA resin (GE Healthcare) according to
the manufacturer's protocol.
Example 4
Transfection and Generation of Live HIV-1

0072 293T cells were grown in a medium containing
DMEM, 10% FBS, and 2 mM L-glutamine at 37° C. in a
humidified atmosphere of 5% CO. When cells reached
60-70% confluency, they were transfected with appropriate
plasmid(s) using Lipofectamine 2000 (10 ul Lipofectamine
2000+3 ug of plasmid(s) for 2 ml cell culture in a 6-well
plate) by following standard procedures provided by the
manufacture (Life Technologies). Six hours posttransfec
tion, the culture medium was carefully removed and
replaced with 2 ml of fresh medium. When it was needed,

Infection Assay
0074 HIV-1 infection was quantified with X-gal staining
based assay with TZM-bl cells. Briefly, virus (generated in
the presence of UAA*), 50 ul 10% DMEM growth medium,
and DEAE-dextran at a final concentration of 40 mg/ml
were added to each well (96-well flat bottom plate) that

contains TZM-bl cells (1x10" per well in 100 ul volume) in

triplicate. Assay controls included: (1) replicate wells of
TZM-bl cells with virus that are generated in the absence of
UAA*; (2) growth medium only control; and (3) TZM-bl
cell only control. After 48-hour incubation at 37°C., 200 ul
of assay medium was removed from each well. Plates were
then washed, fixed, and stained using X-gal Solution fol
lowed by examination using a light microscope.
Example 7
Tissue Culture Infectious Dose 50 (TCID50)
(0075 Infectious titers of all viruses were determined by
standard Tissue Culture Infectious Dose 50 (TCID50)
method with X-gal staining assay (see above) in TZM-bl
cells. Briefly, four-fold serial dilutions of virus were per
formed in quadruplicate (96-well flat bottom plate) in the
X-gal staining assay. The TCID50 of the virus was calcu
lated by Spearman-Karber formula according to the negative
end-point and dilution folds.
Example 8

UAA was added to a final concentration of 1 mM. After

Fluorescence Spectroscopy and Cell Imaging

44-48 hours of incubation, virus-containing culture Super
natant was harvested by collecting the medium from the well
using a pipette. The FBS concentration in the virus-contain
ing culture medium was then adjusted to 20% (i.e. for each
1 ml of harvested virus, 0.125 ml of FBS was added). The
virus-containing culture medium was then filtered through a

0076. The fluorescent images and bright-filed images
were taken by a Nikon ECLIPSE TE3000 microscope and an
EVOS FL Auto Imaging System with DIC. The cells were
excited at 488 nm to acquire EGFP fluorescence images at
530/25 nm.
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Example 9
LC/MS/MS Assays
0077. The corresponding protein band of EGFP-40TAG
from SDS-PAGE was cut and in-gel digested with trypsin (in
50 mMammonium bicarbonate, pH 8.0) overnight at 37°C.
The resulting peptide fragments were extracted with 0.1%
formic acid/75% acetonitrile, and then subjected to LC/MS/
MS analysis using a Waters Q-TOF Ultima. Database
searches were performed on an in-house Mascot server
(Matrix Science Ltd., London, UK). For AZF substitution
site mapping on EGFP. AZF substitution for tyrosine was
included as a variable modification.

Example 10
Suppression Efficiency and Fidelity
0078. To examine the nonsense (e.g., amber) suppression

efficiency and fidelity of the tRNA-AZFRS pair, 293T
cells were co-transfected with a plasmid containing tRNA'."

under the control of a human U6 promoter and the AZFRS
(pAZFRS) with a plasmid encoding EGFP with an amber
mutation at residue 40 (pl.GFP-TAG40). Following trans
fection, cells were cultured in DMEM media (containing
10% FBS and 2 mM L-glutamine) with or without 1 mM
AZF for 12 h before visualization under a fluorescence

microscope (FIGS. 2C and 2D). Full-length EGFP was
detected only in cells supplemented with 1 mM AZF (FIG.
2C), while no EGFP was observed otherwise (FIG. 2D). The
tandem mass spectrometry data (FIG. 9) showed no unde
sirable incorporation of tyrosine or any other natural amino
acids. The amber mutation site contained exclusively
4-aminophenylalanine (aminoF), which is the reduction
product of AZF. These results confirmed the excellent fidel
ity of AZF incorporation, and are consistent with previous
reports on the mass spectrometry analyses of AZF-contain
ing proteins.
Example 11
Suppression of the Gag Protein
007.9 The suppression of an amber codon in the HIV-1
genome was examined next. The Tyr132 codon on the Gag
(group-specific antigen) protein-encoding gene was first
mutated into an amber codon. The resulting pSUMA-Tyr132
was co-transfected into 293T cells with plasmid paZFRS.
After the cells were grown for 48 h in the presence or the
absence of 1 mM AZF, viruses were harvested and the titer

of HIV-1 was analyzed using anti-p24 antibody. The pres
ence and the strength of a blue color Suggest the presence
and the level of the capsid protein p24. As shown in FIG.3A
(Wells #3 and #4), we observed an AZF-dependent p24
synthesis in pSUMA-Tyr132 mutant due to the essential role
of Gag (Gag is processed during maturation to p24.) in p24
protein synthesis. The p24 assay confirmed a very high
fidelity of AZF incorporation (absorbance values of 0.001
versus 0.453 in the absence and the presence of AZF.
respectively; FIG. 3A, Wells #3 and #4). However, only very
low level of p24 synthesis was observed comparing to that
of the wild-type pSUMA control (FIG.3A, Well #1). On the
other hand, a very strong p24 synthesis was observed with

the tRNA'-AclRS pair (FIG. 6, Well #4) and an undetect
able p24 synthesis was observed with the tRNA'-IodoFRS
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pair (FIG. 6, Well #7). Despite amber suppression and the
synthesis of p24, little to no viral infection was observed
when the harvested viruses were used to infect TZM-bl cells

(FIG. 3D and FIGS. 7A, 7D: The TZM-bl cell line stably
expresses large amounts of CD4 and CCR5 and should be
highly sensitive to infections by diverse isolates of HIV-1.
The TZM-bl also contains a genome-copy of beta-galacto
sidase gene under the control of the HIV-1 promoter. The
infection assay is based on the expression level of beta
galactosidase).
0080. To explain the lack of live HIV-1 assembly from
the above experiments, we first examined whether amber
Suppression can negatively affect HIV-1 protein syntheses,
the virion assemble, and/or the infection since HIV-1 uses

seven amber codons as stop signal. To this end, wild-type
pSUMA was co-transfected with plasmid paZFRS into
293T cells. After 48 h of cultivation in the presence of 1 mM
AZF, viruses were harvested and the titer of HIV-1 was

analyzed using anti-p24 antibody. We observed no obvious
difference in p24 synthesis (FIG. 3A, Wells #1 and #2) and
infection rate (FIGS. 3B and 3C) of wild-type pSUMA in the

presence or the absence of the amber suppressing tPNA'"AZFRS pair. To further eliminate the possibility, we con
structed a different HIV-1 mutant that was derived from

pNL-GI (Collins et al., 1998, Nature, 391:964-7), which
contains a copy of GFP inserted at the nef locus. In this new
HIV-1 construct, an amber mutation was made at position 40
of GFP (originally encoding a tyrosine residue) and there
was no amber mutation on the HIV-1 protein-encoding
genes. The resulting HIV-1 variant, pNL-GI-Tyr10, was
transfected into 293T cells together with plasmid paZFRS.
Strong GFP fluorescence (FIG. 4B) was detected when 1
mM of AZF was included in the culture medium. The

fluorescence intensity is comparable to the wild-type pNL
GI (FIG. 4A), which indicated a very efficient amber Sup

pression with the tRNA'-AZFRS pair. The produced HIV-1

viruses were then harvested and used to infect TZM-bl cells.

Near wild-type infection was observed (FIGS. 4C and 4D).
Based on the above observations, we concluded that amber

suppression did not have detectable detrimental effects on
the viability of HIV-1.
I0081. It was then tested to see if UAA* incorporation at
Tyr132 of Gag protein interfered with either the proper
function or the post-translational processing of the Gag
protein. To this end, the pSUMA-Tyr132 mutant was trans

fected into 293T cells with a plasmid containing trNA'-

TyrRS pair. The amber suppression led to the incorporation
of a tyrosine residue at position 132, which produced the
wild-type Gag protein. The p24 (FIG. 3A, Well #5) and
infection (FIG. 3F) assays showed that the pSUMA-Tyr132
mutant, after amber Suppression, had near wild-type activi
ties. As a control, when pSUMA-Tyr132 was transfected

into 293T cells that did not contain the tRNA'-TyrRS pair,

no p24 synthesis was detected (FIG. 3A, Well #6) and no
live viruses was assembled according to the infection assay
(FIG. 3G). Combining these results and the results from
UAA* incorporation, we concluded that incorporation of
UAA* at position Tyr132 must have negative effect on the
Gag protein expression and/or function.
Example 12
Suppression of the Gag or Pol Protein
0082 We next decided to examine other mutation sites
and generated two new HIV-1 mutants, with amber mutation

US 2016/0375128A1

at Alal 19 of Gag (pSUMA-Ala119) or Leu365 of Pol
(pSUMA-Leu365). We initially focused on the amber sup

pression with the tRNA'."-AZFRS pair in the presence of

AZF. We observed an AZF-dependent p24 synthesis in
pSUMA-Alal 19 (FIG. 3A, Wells #7 and #8). The amber
suppression at Ala119 position (FIG. 3A, Well #8) was
apparently stronger than that at position Tyr132 of Gag
(FIG. 3A, Well #4) and has similar good fidelity (absorbance
values of 0.000 versus 2.127 in the absence and the presence
of AZF, respectively; FIG. 3A, Wells #7 and #8). On the
other hand, the synthesis of p24 in pSUMA-Leu365 was not
AZF-dependent (FIG.3A, Wells #9 and #10) since the amber
mutation is in Pol, which does not affect p24 synthesis. Both
mutants showed infection (FIGS. 3H and 31) but with much
lower activity than that of wild-type pSUMA (FIG. 3B). As
a control, no infection was observed when AZF was not

provided in the culture medium of 293T cells after trans

fection (FIGS. 8A, 8B). We next examined the tRNA
AcFRS pair and tRNA'-IodoFRS pair. As shown in FIG.

6, a range from non-detectable to relative strong amber
suppression was observed with the two tRNA-aaRS pairs
and the different amber mutation sites (FIG. 6, Wells #5, #6,
#8, and #9). However, no infection was detected when the

tRNA'-AcPRS pair and tRNA'."-IodoFRS pair were used

to generate pSUMA-Ala 119 and pSUMA-Leu365 mutants
(FIGS. 7B, 7C, 7E, and 7F). Since the amber suppression
efficiency did not correlate well with the infection results,
we suspected that the structure of UAA*s and the incorpo
ration sites might still partially interfere with the protein
function.

Example 13
Suppression of the Protease Protein
I0083. An additional mutation site, TyrS9TAG (pSUMA
TyrS9) of HIV-1 protease was then examined. Since TyrS9
has similar structure to AZF and is away from the active site
(PDB 1 EBZ), mutation of which to AZF might not cause
undesired disturbance of protein structure and function.
Indeed, the pSUMA-TyrS9 mutant showed better infection
activity (FIG. 5B) than that of the pSUMA-Alal 19 (FIG.
3H) and pSUMA-Leu365 (FIG. 3I). As a control, no live
pSUMA-TyrS9 virus was produced in the absence of AZF
during viral assembly in 293T cells according to the infec
tion assay (FIG. 8C). A comparison between the observed
Tissue Culture Infectious Dose 50 (TCID50) values in the
presence (1.31x103) and the absence of AZF (0.00) impli

cates high fidelity of the tRNA-AZFRS pair.

0084. The results above indicate that the UAA*-mediated
Suppression strategy can be used to produced live HIV-1 and
the resulting virus is infectious. Since the infected cells do
not contain the necessary Suppression machinery (the special
tRNA-aaRS pair and UAA*) that is required for HIV-1
assembly, no new virus can be assembled after the initial
infection.

Example 14
All-in-One pSUMA Vector for In Vivo Experiments
0085. In order to further examine the feasibility of con
trolling multiple cycles of HIV-1 replication with unnatural
amino acid-mediated amber Suppression, we needed to gen
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erate HIV-1 mutants that contain a genomic insertion of an
amber Suppressor tRNA and its corresponding aminoacyl
tRNA synthetase.
I0086 According to previous reports, the nefregion of the
HIV-1 genome tolerates deletions and/or insertions. We have
obtained pSUMA-d1 d2 constructs in which two regions of
the nef gene were deleted. We examined the infectivity of
pSUMA-d1 d2 in humanized-BLT mice and demonstrated
that pSUMA-d1 d2 has near wild-type infectivity.
I0087. We next constructed pSUMA-d1 d2-U6-tRNA by
inserting U6-promoter-RNA-terminator cassette into the
deleted nef region of HIV-1 genome. We also constructed
pSUMA-d1 d2-AZFRS and pSUMA-d1 d2-TyrRS by insert
ing AZRS (for the incorporation of p-azido-phenylalanine)
and TyrRS (for the incorporation of tyrosine), respectively,
into the nef region of the HIV-1 genome. All three modified
viruses showed weak infection. The results indicated that

insertion into the nefregion of genes of this size reduces the
infectivity of virus.
I0088 Since gene insertion in the nef region is not well
tolerated, we next focused on a region between env and nef.
A model viral genome, pSUMA-EGFP, was constructed by
inserting an EGFP gene between the env and the nef region.
After transfection, cells containing pSUMA-EGFP showed
strong green fluorescence. The result indicated that the
inserted EGFP could be successfully expressed. Next, we
infected TZM-bl cell with pSUMA-EGFP-derived virus. A
comparable infectivity to that of wild-type HIV-1 was
observed. These results indicated that a large gene could be
inserted between env and nef with no apparent effects on
virus replication and infection.
I0089 pSUMA-AZFRS and pSUMA-TyrRS have been
constructed and are evaluated, in the presence of a corre
sponding aminoacyl-tRNA synthetase, in humanized-BIT
1CC.

Example 15
HIV Containing Two Amber Mutations
0090. To examine if the suppression of two amber codons

on the HIV-1 genome by the tRNA'-AZFRS pair is suffi

ciently attenuated but still able to efficiently produce mean
ingful amounts of live HIV, an HIV-1 mutant was con
structed having two amber mutations, Trp36 and Gln127
within the matrix domain (MA) of the Gag protein
(pSUMA-Trp36Gln127). The positions were selected using
the crystal structure of the MA protein (see PDB: 2H3F) and
because they are not key residues for MAs interaction with
phosphatidylinositol 4,5-bisphosphate. In addition, these
mutation sites are located relative early on the HIV-1
genome, which reduces the chance of interference with the
alternative reading frame and post-translational processing
of the HIV proteins. Encouragingly, similar infection activ
ity was observed with pSUMA-Trp36Gln127 (FIG. 5C)
compared to an HIV-1 containing a single amber mutation
(FIG. 5B). As a control, no live pSUMA-Trp36Gln127 virus
was produced in the absence of AZF during viral assembly
in 293T cells according to the infection assay (FIG. 8D).
Example 16
Light-Activated Replication of HIV-1
0091 To add an additional regulatory element to control
HIV-1 replication, HIV-1 mutants were generated that only
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replicate in the presence of 365 nm UV light. As shown in
FIG. 10, an essential tyrosine or lysine residue in an HIV-1
protein is genetically replaced with o-nitrobenzyl-O-tyro
sine (ONBY) or o-nitrobenzyl-oxycarbonyl-Ne-L-lysine
(ONBK), respectively. With exposure to UV light, ONBYor
ONBK is converted back to tyrosine or lysine, respectively,
and the function of the protein is restored.
0092. To examine the fidelity and efficiency of the
genetic incorporation of ONBY and ONBK, the expression
level of EGFP-Y39TAG, which contains an amber codon at

position 39, was examined. As shown in FIG. 11, strong
green fluorescence was only observed in samples Supple
mented with ONBY (FIG. 10A) or ONBK (FIG. 10C).
Extremely weak signals were detected in samples without
unnatural amino acids, which indicated an acceptable fidel
ity and efficiency.
0093. Next, HIV-1 viability was tested after UV treat
ment. After being exposed to 365 nm UV light for 0, 5, 10,
20, or 30 minutes, HIV-1 viruses ware applied to TZM-bl
cells and the infectivity of the viruses were examined No
obvious detrimental effects were observed for the UV

treated Samples compared with non-treated control (0 min
ute sample). It was concluded that 365 nm UV light does not
reduce virus infectivity.
0094 ONBY and ONBK have been successfully incor
porated into essential HIV-1 proteins, including the group
specific antigen (Gag) and the protease.

6-8 week old female NSG (NOD/scid-ycnull) mice (Stock
Number 005557, Jackson lab).
0096. Three groups of hu-BLT mice (n=5) are exposed to
a) wild-type pSUMA, b) pSUMA-tRNA-aaRS
Trp36Gln127 (a pSUMA-Trp36Gln127 variant that contains
a genomic copy of Suppressor tRNA and the corresponding
aminoacyl-tRNA synthetase genes) with UAA*, or c)
pSUMA-tRNA-aaRS-Trp36Gln127 without UAA*, and
examined After intraperitoneal (i.p.) inoculation of virus at
10x10, TCIDso UAA* is administered intraperitoneally to
hu-BLT mice in the “pSUMA-tRNA-aaRS-Trp36Gln127
with UAA group'. The plasma viral load of HIV-1 RNA in
mice is monitored using real time qRT-PCR assay to deter
mine if replication of pSUMA-tRNA-aaRS-Trp36Gln127 is
tightly controlled with the availability of UAA*. The wild
type pSUMA is used as a positive control.
0097. It is to be understood that, while the methods and
compositions of matter have been described herein in con
junction with a number of different aspects, the foregoing
description of the various aspects is intended to illustrate and
not limit the scope of the methods and compositions of
matter. Other aspects, advantages, and modifications are
within the scope of the following claims.
0.098 Disclosed are methods and compositions that can
be used for, can be used in conjunction with, can be used in
preparation for, or are products of the disclosed methods and
compositions. These and other materials are disclosed
herein, and it is understood that combinations, Subsets,

dendritic and natural killer cells in both mucosal and sec

interactions, groups, etc. of these methods and compositions
are disclosed. That is, while specific reference to each
various individual and collective combinations and permu
tations of these compositions and methods may not be
explicitly disclosed, each is specifically contemplated and
described herein. For example, if a particular composition of
matter or a particular method is disclosed and discussed and
a number of compositions or methods are discussed, each
and every combination and permutation of the compositions
and the methods are specifically contemplated unless spe
cifically indicated to the contrary. Likewise, any Subset or
combination of these is also specifically contemplated and

ondary lymphatic tissues. Hu-BLT mice are generated from

disclosed.

Example 17
In Vivo Control of HIV Replication in a
Humanized Mouse

0095 To evaluate the live, attenuated HIV vaccine, the in
Vivo replication capacity and kinetics of the vaccine are
examined in humanized mice (hu-BLT mice). The Hu-BIT
mouse can reconstitute all major human hematopoietic lin
eages, including CD4+, CD8+T, B, monocyte/macrophage,

SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS: 23
<21 Os SEQ ID NO 1
&211s LENGTH: 25
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs SEQUENCE: 1

ctagaacgat tcgcagttaa cc ctd

25

<21 Os SEQ ID NO 2
&211s LENGTH: 37
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs SEQUENCE: 2

gttctgcact at aggctaat tttggctgac Ctggctg

37
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<210s, SEQ ID NO 3
&211s LENGTH: 24
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 3

tagcctatag togcagaacct c cag

24

<210s, SEQ ID NO 4
&211s LENGTH: 24
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 4

gtgcctatag citttgttgtcc acag

24

<210s, SEQ ID NO 5
&211s LENGTH: 25
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
< 4 OO

SEQUENCE: 5

ctagaacgat t cqcagttaa ccctg

25

<210s, SEQ ID NO 6
&211s LENGTH: 4 O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 6

titt.cctg.cgt cagcctatgc titgctgtgct tttitt cittac

4O

<210s, SEQ ID NO 7
&211s LENGTH: 23
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OO > SEQUENCE: 7

Ctgacgcagg aaacaa.ca.gc cag

23

<210s, SEQ ID NO 8
&211s LENGTH: 24
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 8

gtgcctatag citttgttgtcc acag
<210s, SEQ ID NO 9
&211s LENGTH: 27

24
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&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 9

caaagtaaga caatatgatc aggtaac

27

<210s, SEQ ID NO 10
&211s LENGTH: 29
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 10

cacctic taca gatgttct ct cagttcctic

29

<210s, SEQ ID NO 11
&211s LENGTH: 28
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 11

Catctgtaga ggtggggatt taccacac

28

<210s, SEQ ID NO 12
&211s LENGTH: 24
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 12

gct tcc catgtttct ctittg tatg

24

<210s, SEQ ID NO 13
&211s LENGTH: 25
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 13

ctagaacgat t cqcagttaa ccctg

25

<210s, SEQ ID NO 14
&211s LENGTH: 43
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 14

atttctatgg ttacct gatc ctattgtc.tt actittgataa aac
<210s, SEQ ID NO 15
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide

43
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<4 OOs, SEQUENCE: 15

gtagaggat C Cactagtaac
<210s, SEQ ID NO 16
&211s LENGTH: 36
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 16

tagctic cctd cittgcctata ctatatgttt taattg

36

<210s, SEQ ID NO 17
&211s LENGTH: 2O
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 17

ggcaa.gcagg gagctagaac
<210s, SEQ ID NO 18
&211s LENGTH: 24
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 18

gtgcctatag citttgttgtcc acag

24

<210s, SEQ ID NO 19
&211s LENGTH: 22
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 19

gctatalagac gcgt.ccacca t

22

<210s, SEQ ID NO 2 O
&211s LENGTH: 19
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 2O

Cctaggtggc atcgcc ct c

19

<210s, SEQ ID NO 21
&211s LENGTH: 34
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 21

cgatgccacc tagggaaagc tigacic ctgaa gttc

34
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<210s, SEQ ID NO 22
&211s LENGTH: 26
&212s. TYPE: DNA

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic oligonucleotide
<4 OOs, SEQUENCE: 22

cgt.ctagatt acttgtacag ct catc

26

<210s, SEQ ID NO 23
&211s LENGTH: 16
212. TYPE: PRT

<213> ORGANISM: Artificial Sequence
22 Os. FEATURE:

<223> OTHER INFORMATION: synthetic peptide
<4 OOs, SEQUENCE: 23

Phe Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Ala Phe Gly Lys
1.

5

10

1. A live, attenuated HIV vaccine, wherein the genome of
the HIV comprises at least one first mutation in an essential
region, wherein the first mutation is a nonsense mutation.
2. The live, attenuated HIV vaccine if claim 1, wherein the

essential region is the protease gene.

3. The live, attenuated HIV vaccine of claim 1, wherein

the genome of the HIV further comprises at least one
transgene in a non-essential region, the transgene encoding
a Suppressor tRNA and a corresponding aminoacyl-tRNA
synthetase.
4. The live, attenuated HIV vaccine of claim 3, wherein

15

10. The method of claim 9, further comprising exposing
the infected host cell to light.
11. The method of claim 10, wherein the light is UV light.
12. The method of claim 11, wherein the UV light is 365
nm light.
13. The method of claim 9, wherein the host cell com

prises at least one transgene encoding a Suppressor tRNA
and a corresponding aminoacyl-tRNA synthetase.
14. An article of manufacture for producing a live, attenu
ated HIV Vaccine, comprising:

the non-essential region is between the env gene and the nef

the live, attenuated HIV vaccine of claim 1; and

gene.

at least one unnatural amino acid (UAA).

5. The live, attenuated HIV vaccine of claim 1, wherein

the genome of the HIV further comprises at least one second
mutation in an essential region, wherein the second mutation
results in a codon encoding for an unnatural amino acid,
wherein the unnatural amino acid is a photoreactive amino
acid.

6. The live, attenuated HIV vaccine of claim 5, wherein

the photoreactive amino acid is a photocaged amino acid.
7. The live, attenuated HIV vaccine of claim 6, wherein

the photocaged amino acid is selected from the group
consisting of ONBK and ONBL.
8. The live, attenuated HIV vaccine of claim 5, wherein

the essential region is the gag gene or the protease gene.
9. A method of making a live, attenuated HIV vaccine,
comprising:
infecting a host cell with the live, attenuated HIV vaccine
of claim 1; and

purifying the live, attenuated HIV vaccine.

15. The article of manufacture of claim 14, further com

prising a host cell.
16. The article of manufacture of claim 15, wherein the

host cell comprises at least one transgene encoding a first
suppressor tRNA and a first corresponding aminoacyl-tRNA
synthetase pair that recognizes the unnatural amino acid.
17. The article of manufacture of claim 16, further com

prising a photoreactive amino acid.

18. The article of manufacture of claim 14, wherein the

UAA* is a photoreactive amino acid.
19. The article of manufacture of claim 17, wherein the

host cell further comprises at least one transgene encoding
a second Suppressor tRNA and a second corresponding
aminoacyl-tRNA synthetase pair that recognizes the photo
reactive amino acid.

